Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer. There is an urgent need to develop tools to identify individuals at high risk of developing SCLC. We have previously reported that the cytokinesis-blocked micronucleus (CBMN) assay is a strong predictor of non-small cell lung cancer (NSCLC). Here, we investigate the sensitivity of the CBMN endpoints as predictors of SCLC risk. We conducted the CBMN assay on SCLC patients (n = 216), NSCLC patients (n = 173), and healthy controls (n = 204). Per sample, 1,000 binucleated cells (BN) were scored, and 3 endpoints, micronuclei (BN-MN), nucleoplasmic bridges (BN-NPB), and nuclear buds(BN-BUD), were recorded. Spectral karyotyping was also conducted on SCLC patients (n = 116) and NSCLC patients (n = 137) to identify genomic regions unique to each disease. Significantly higher levels of CBMN endpoints were observed in both cancer groups compared to controls. BN-NPBs were significantly higher among SCLC patients compared to NSCLC patients (p < 0.001). Chromosomes 5 and 17 were associated with BN-MN, and chromosomes 5, 18, 20, and 22 were associated with BN-NPBs in SCLC patients. Given the high frequency of chromosome aberrations observed in SCLC, events such as reinsertion of the micronucleus and chromothripsis may be potential mechanisms for the genetic instability in these patients.

Journal Section:
Editor's choice
Keywords:
Cytokinesis-blocked micronucleus assay, Genetic instability, Non-small cell lung cancer, Small cell lung cancer
1.
Argiris A, Murren JR: Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 7:437-447 (2001).
2.
Balsara BR, Testa JR: Chromosomal imbalances in human lung cancer. Oncogene 21:6877-6883 (2002).
3.
Baykara O, Bakir B, Buyru N, Kaynak K, Dalay N: Amplification of chromosome 8 genes in lung cancer. J Cancer 6:270-275 (2015).
4.
Bonassi S, Hagmar L, Stromberg U, Montagud AH, Tinnerberg H, et al: Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 60:1619-1625 (2000).
5.
Bonassi S, Znaor A, Norppa H, Hagmar L: Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenet Genome Res 104:376-382 (2004).
6.
Bonassi S, El-Zein R, Bolognesi C, Fenech M: Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis 26:93-100 (2011).
7.
Byers LA, Rudin CM: Small cell lung cancer: where do we go from here? Cancer 121:664-672 (2015).
8.
Cooper S, Spiro SG: Small cell lung cancer: treatment review. Respirology 11:241-248 (2006).
9.
Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, et al: DNA breaks and chromosome pulverization from errors in mitosis. Nature 482:53-58 (2012).
10.
D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, et al: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339-346 (1992).
11.
Dave BJ, Hopwood VL, Hughes JI, Mellilo D, Jackson GL, Pathak S: Nonrandom chromosomal abnormalities in lymphocyte cultures of individuals with colorectal polyps and of asymptomatic relatives of patients with colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 2:587-591 (1993).
12.
Dave BJ, Hopwood VL, King TM, Jiang H, Spitz MR, Pathak S: Genetic susceptibility to lung cancer as determined by lymphocytic chromosome analysis. Cancer Epidemiol Biomarkers Prev 4:743-749 (1995).
13.
Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117:294-299 (2005).
14.
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075 (2008).
15.
El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR: Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res 66:6449-6456 (2006).
16.
El-Zein RA, Fenech M, Lopez MS, Spitz MR, Etzel CJ: Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers. Cancer Epidemiol Biomarkers Prev 17:1111-1119 (2008).
17.
El-Zein RA, Lopez MS, D'Amelio AM Jr, Liu M, Munden RF, et al: The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev 23:2462-2470 (2014).
18.
Fenech M: The in vitro micronucleus technique. Mutat Res 455:81-95 (2000).
19.
Fenech M: Biomarkers of genetic damage for cancer epidemiology. Toxicology 181-182:411-416 (2002a).
20.
Fenech M: Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today 7:1128-1137 (2002b).
21.
Fenech M: Cytokinesis-block micronucleus cytome assay. Nat Protocol 2:1084-1104 (2007).
22.
Fenech M, Morley AA: Measurement of micronuclei in lymphocytes. Mutat Res 147:29-36 (1985).
23.
Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, et al: HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 534:65-75 (2003).
24.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917 (2010).
25.
Franklin WF, Noguchi M, Gonzalez A: Molecular and cellular pathology of lung cancer, in Pass HI, Carbone DP, Johnson DH, Minna JD, Scagliotti GV, Turrisi AT (eds): Principles and Practice of Lung Cancer, ed 4, pp 287-324 (Lippincott Williams & Wilkins, Philadelphia 2010).
26.
Garnis C, Campbell J, Davies JJ, Macaulay C, Lam S, Lam WL: Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. Hum Mol Genet 14:475-482 (2005).
27.
Gjayee H, Dinney C, Pathak S: Do lymphocytes contain chromosomal lesions that are also stable markers in cancer cells? Inter J Oncology 11:681-684 (1997).
28.
Greene FL: Staging of colon and rectal cancer: from endoscopy to molecular markers. Surg Endosc 20:S475-478 (2006).
29.
Haga Y, Hiroshima K, Iyoda A, Kohno H, Shibuya K, et al: Frequency of loss of heterozygosity at 3 p, 9 p, 13 q, and 17 p is related to proliferative activity in smokers with stage I non-small cell lung cancer. Thorac Cardiovasc Surg 53:114-117 (2005).
30.
Hassan WA, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, Ito T: Notch1 controls cell invasion and metastasis in small cell lung carcinoma cell lines. Lung Cancer 86:304-310 (2014).
31.
Hintzsche H, Hemmann U, Poth A, Utesch D, Lott J, et al: Fate of micronuclei and micronucleated cells. Mutat Res 771:85-98 (2017).
32.
Hu Z, Wu C, Shi Y, Guo H, Zhao X, et al: A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 43:792-796 (2011).
33.
Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, et al: Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer 52:802-816 (2013).
34.
Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, et al: Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25:130-138 (2006).
35.
Kim YH, Kwei KA, Girard L, Salari K, Kao J, et al: Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 29:1421-1430 (2010).
36.
Larsen JE, Minna JD: Molecular biology of lung cancer: clinical implications. Clin Chest Med 32:703-740 (2011).
37.
Liou SH, Lung JC, Chen YH, Yang T, Hsieh LL, et al: Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res 59:1481-1484 (1999).
38.
Ma J, Gao M, Lu Y, Feng X, Zhang J, et al: Gain of 1q25-32, 12q23-24.3, and 17q12-22 facilitates tumorigenesis and progression of human squamous cell lung cancer. J Pathol 210:205-213 (2006).
39.
Masuda A, Takahashi T: Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 21:6884-6897 (2002).
40.
McHugh MK, Lopez MS, Ho CH, Spitz MR, Etzel CJ, El-Zein RA: Use of the cytokinesis-blocked micronucleus assay to detect gender differences and genetic instability in a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev 22:135-145 (2013).
41.
Miller CW, Simon K, Aslo A, Kok K, Yokota J, et al: p53 mutations in human lung tumors. Cancer Res 52:1695-1698 (1992).
42.
Nishikawa N, Toyota M, Suzuki H, Honma T, Fujikane T, et al: Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 67:9649-9657 (2007).
43.
Norppa H, Bonassi S, Hansteen IL, Hagmar L, Strömberg U, et al: Chromosomal aberrations and SCEs as biomarkers of cancer risk. Mutat Res 600:37-45 (2006).
44.
Pathak S, Hopwood VL, Hortobagyi GN, Jackson GL, Hughes JI, Melillo D: Chromosome anomalies in human breast cancer: evidence for specific involvement of 1q region in lymphocyte cultures. Anticancer Res 11:1055-1060 (1991).
45.
Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, et al: Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 31:282-287 (2001).
46.
Petersen I, Petersen S, Bockmühl U, Schwendel A, Wolf G, Dietel M: Comparative genomic hybridization of bronchial carcinomas and their metastases (in German). Verh Dtsch Ges Pathol 81:297-305 (1997).
47.
Qian J, Massion PP: Role of chromosome 3q amplification in lung cancer. J Thorac Oncol 3:212-215 (2008).
48.
Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593-602 (2007).
49.
Reynisdottir I, Arason A, Einarsdottir BO, Gunnarsson H, Staaf J, et al: High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. Cancer Med 2:437-446 (2013).
50.
Ruark E, Seal S, McDonald H, Zhang F, Elliot A, et al: Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat Genet 45:686-689 (2013).
51.
Saldivar JC, Shibata H, Huebner K: Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem 109:858-865 (2010).
52.
Schwartz AG, Wenzlaff AS, Bock CH, Ruterbusch JJ, Chen W, et al: Admixture mapping of lung cancer in 1812 African-Americans. Carcinogenesis 32:312-317 (2011).
53.
Slorach EM, Chou J, Werb Z: Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev 25:471-484 (2011).
54.
Smerhovsky Z, Landa K, Rössner P, Brabec M, Zudova Z, et al: Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ Health Perspect 109:41-45 (2001).
55.
Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, et al: A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 109:17034-17039 (2012).
56.
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40 (2011).
57.
Stewenius Y, Gorunova L, Jonson T, Larsson N, Höglund M, et al: Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci USA 102:5541-5546 (2005).
58.
Tucker JD, Preston RJ: Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat Res 365:147-159 (1996).
59.
Umegaki K, Fenech M: Cytokinesis-block micronucleus assay in WIL2-NS cells: a sensitive system to detect chromosomal damage induced by reactive oxygen species and activated human neutrophils. Mutagenesis 15:261-269 (2000).
60.
van Meerbeeck JP, Fennell DA, De Ruysscher DK: Small-cell lung cancer. Lancet 378:1741-1755 (2011).
61.
Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, et al: Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 107:13040-13045 (2010).
62.
Wali A: FHIT: doubts are clear now. Scientific World Journal 10:1142-1151 (2010).
63.
Wistuba II, Gazdar AF, Minna JD: Molecular genetics of small cell lung carcinoma. Semin Oncol 28:3-13 (2001).
64.
Worden FP, Kalemkerian GP: Therapeutic advances in small cell lung cancer. Expert Opin Investig Drugs 9:565-579 (2000).
65.
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, et al: Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65:5561-5570 (2005).
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.